solid quarter question xarelto
darzalex initi diagnosi
bottom line report solid revenu estim
vs consensus/c non-gaap ep
cs consensu rel
estim modest miss larg due lower-than-expect non-
oper incom also increas revenu guidanc
increas midpoint
increas ep midpoint vs
prior penni higher current consensu cs
notabl point quarter includ pharma consum
segment perform slightli better expect medic devic
sale littl light pharma specif imbruvica anti-
psychot franchis notabl strong remicad zytiga also
perform well less import stage life cycl xarelto
darzalex notabl light look insight
dynam two product call
confer call dial-in
expect call focu compani see futur growth key
driver stelara imbruvica xarelto darzalex come given recent
data releas competit dynam market expect
key pipelin product esketamin erdafitinib
compani busi develop prioriti new cfo place
nearli two year announc actelion acquisit
compani perspect latest dynam around us drug price ahead
us midterm elect follow step
administr recent taken issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
summari jnj result along comparison estim prior report figur
provid figur error refer sourc found
us million unless otherwis state
sale
sale
sale
compani data credit suiss estim streetaccount foa consensu
compani mention price
